Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic • tnbc
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
Would clinical stage or nodal status affect your decision?
Answer from: Medical Oncologist at Community Practice
The brief answer is yes, I would. These patients were included in the CREATE-X trial (Masuda et al., PMID 28564564). Also, there is data out of Boston that following neoadjuvant chemotherapy, patients with even isolated tumor cells in lymph nodes have a poorer prognosis (Wong et al., PMID 31228134)....
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I would consider ITCs and/or LVI to be residual disease. This exact scenario hasn't come up for me (yet) as a clinical scenario but I would likely follow the same strategy that I do all TN breast cancer patients with residual disease post NAC. I recommend adjuvant capecitabine for all patients with ...